Login to Your Account



Clinic Roundup


Thursday, May 9, 2013

• Portola Pharmaceuticals Inc., of South San Francisco, Calif., reported safety and efficacy data from a Phase II proof-of-concept study of PRT4445 of Eliquis (apixaban) in healthy volunteers. Eliquis is a Factor Xa inhibitor. Anticoagulation markers and plasma concentration levels of Eliquis indicate that PRT 4445 results in a rapid, sustained, dose-related reversal of anticoagulant activity of Eliquis. There were no serious adverse events.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription